Table 1 Pharmacological treatment of patients with systemic lupus erythematosus included in the study, at the time the lumbar puncture was performed
Treatment | NPSLE (n = 36) | No NPSLE (n = 71) | Antiphospholipid antibody syndrome (n = 7) |
|---|---|---|---|
Prednisolone (≤ 10 mg) | 15 (42%) | 39 (55%) | 1 (14%) |
Prednisolone (> 10 mg) | 3 (8%) | 13 (18%) | 0 (0%) |
No prednisolone | 16 (58%) | 21 (30%) | 5 (29%) |
Antimalarials | 3 (8%) | 7 (10%) | 0 (0%) |
Azathioprine | 2 (6%) | 8 (11%) | 2 (29%) |
Azathioprine+ cyclosporin A | 2 (6%) | 2 (3%) | 0 (0%) |
Methotrexate | 2 (6%) | 1 (1.5%) | 0 (0%) |
Cyclosporin A | 1 (3%) | 6 (8%) | 1 (14%) |
Cyclophosphamide | 11 (31%) | 11 (15%) | 0 (0%) |
Cyclophosphamide+ cyclosporin A | 3 (8%) | 1 (1.5%) | 0 (0%) |
Cyclophosphamide+antimalarials | 1 (3%) | 1 (1.5%) | 0 (0%) |
No cytotoxic drug | 11 (31%) | 34 (48%) | 4 (57%) |
Antihypertensive treatment | 12 (33%) | 18 (25%) | 1 (14%) |
Low-dose aspirin | 7 (19%) | 17 (24%) | 3 (43%) |
Warfarin | 3 (8%) | 0 (0%) | 2 (29%) |